Materials Innovation for Human Flourishing. Eudaemon Tech is building next generation medical devices and applications of material sciences including advanced manufacturing capabilities.

The University of Queenslands Australian Institute for Bioengineering and Nanotechnology (AIBN) is an integrated multi-disciplinary research institute bringing together the skills of world-class researchers in the areas of bioengineering and nanotechnology. It is home to 18 research groups working at the interface of the biological, chemical and physical science to alleviate current problems in human health and environmental issues. The Institute has three key areas that collectively distinguish it from other institutes in the country, namely AIBNs: - Research excellence; - Industry focus; and - Dynamic research environment. These characteristics focus AIBN research efforts on developing new products, processes and devices for improving human health and quality of life. In this way the Institute goes beyond basic research to promote and develop the growth of innovative industries, which will benefit the Queensland and Australian economies.

Loam works with 4.5 billion years of evolution to solve the climate crisis. Microbes have changed the composition of our atmosphere through earths history. At Loam, we are ensuring these organisms can do it again. Through a better understanding of how microbes influence the carbon cycle, we can create new planetary-scale opportunities for carbon sequestration and improve agricultural productivity.

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product, DMX-200, for kidney diseases and for respiratory complications associated with COVID-19. Dimerix has three Phase 3 clinical programs with near term value propositions 1) Global Phase 3 REMAP-CAP study in at least 200 hospitalised COVID-19 patients with respiratory pneumonia in Europe and UK 2) Multi-national Phase 3 CLARITY 2.0 study in at least 600 COVID-19 patients with respiratory complications in India 3) Global Phase 3 study in Focal Segmental Glomerulosclerosis (FSGS) patients, which is a rare kidney disease, following positive Phase 2 data in 2020 and for which Dimerix has been granted Orphan Drug Designation by the FDA and EMA Dimerix also has longer term programs in Diabetic Kidney Disease and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD).

Ecogreen is a Melbourne-based biotechnology company producing innovative and low-impact products that fund high-impact climate projects. We offer a growing range of cleaning, well-being, and waste management solutions for commercial and domestic applications. Ecogreen is constantly evolving through the creation and piloting of new concepts, products, and projects. We never stop pushing our products and projects to the limits of sustainability, and do all of this while motivating others to do the same. Collaboration, transparency, and radical honesty is what drives our processes, vision, and overall way of thinking. For us, it is about connecting science and enterprise through collaborative projects, with our ultimate goal to create solutions through viable new eco-compatible industries. Its all part of our Philosophy of Better; a belief that sustainability isnt a destination but a direction with each day spent improving on the last and planning for the next; to do better, to BE bet…

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAAs subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated $3.4 million in sales of goods & services in FY 2022. PAAs lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of …

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the bodys immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. ASX: IMU

𝗔 𝘄𝗼𝗿𝗹𝗱 𝗼𝗳 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝗶𝗲𝘀. Our vision of a world of breakthrough discoveries defines our whole purpose. With science at its height in the greatest period of research advancement, we see an ideal world of breakthrough discoveries. 𝗪𝗲𝘀𝘁𝗹𝗮𝗯 𝗶𝗻 𝗲𝘃𝗲𝗿𝘆 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆. Westlabs mission is for Westlab to be in every discovery. Your discoveries make our world a better place. Were here for you, in the same way, science is here for mankind. We want you to say that “Westlab played a part in my success”, with solutions that let people on the scientific forefront to do their best work.

CropLife Australia (CropLife) is the peak industry organisation representing the agricultural chemical and biotechnology (plant science) sector in Australia. CropLife represents the innovators, developers, manufacturers, formulators and registrants of crop protection and agro-biotechnology products. CropLife Australia advocates science based legislative frameworks that are consistent in approach and application across the industry. CropLife promotes competitiveness through innovation, the protection of intellectual property and the introduction of new technologies and practices. Our members develop and register products to protect crops against pests, weeds and diseases, and develop crop biotechnologies that are key to the nations agricultural productivity and sustainability as well as global food security.

MTPConnect is the Medical Technologies and Pharmaceuticals Industry Growth Centre in Australia. MTPConnect is part of the Industry Growth Centres Initiative, an industry-led approach to drive innovation, productivity and competitiveness by concentrating our investment on key industry sectors. MTPConnect will cast a commercial eye on all aspects of the medical technology and pharmaceutical industries and identify players with the ability to innovate products and services that will drive jobs in Australia. The aim for MTPConnect is to boost the sectors competitive advantage and establish Australia as an Asia Pacific hub for medical technology and pharmaceutical companies by: • Identifying opportunities to reduce regulatory burden; • Increasing collaboration and commercialization; • Improving capabilities to engage with international markets and global supply chains; and • Enhancing management and workforce skills.

The Mark Bouw Group delivers leading strategic advisory services for a clients across the globe from a range of industries specialising in the Med Tech, Consumer and Technology markets. Mark and his high performing team collaborate with CEOs, Company Directors and Business Owners to develop and implement the strategies required for their businesses to prosper. Mark Bouw Group specialises in finding practical strategy solutions for its clients that are cost effective and valuable long-term. Our core services include: 1. Manage establishment and operations of Australian entities for off-shore parent companies, 2. Strategic Advisory to grow and manage Australian businesses, 3. Facilitation of Government Grants. 4. Strategic Marketing and Creative Services. With over a decade of experience the Mark Bouw Group know how to Do Business in Australia.

Sydney-based CRO Southern Star Research can access the financial, operational and regulatory advantages of conducting clinical trials in Australia. This local knowledge, as well as our full-service offering, enables our biotechnology, pharmaceutical and medical device customers to benefit from the Australian environment. We have expertise in a broad range of indications, and a Clinical Team who have an average of 17 years direct clinical research experience. Furthermore, all of our work is underpinned by a passion for cutting edge science, a keen interest in early stage clinical development and a willingness to provide every client with exceptional customer service. With a track record of success in clinical trials spanning Phase I to IV, Southern Star Research has both the capability and the drive to support your R&D objectives in Australia and Asia-Pacific.

Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain affecting memory, cognitive function, behaviour and neuropsychological symptoms. Actinogens lead compound, Xanamem, has been specifically designed to reduce production of intracellular cortisol - the stress hormone - through the inhibition of the 11β-HSD1 enzyme in the brain. The 11β-HSD1 enzyme is highly concentrated in the areas of the brain associated with cognitive impairment in early Alzheimers Disease (AD) and Depression, and other neurological and psychiatric diseases. Because of its ability to reach these areas of the brain and inhibit this enzyme, Xanamem is very different from other treatments for cognitive impairment. Actinogen has studied 11β-HSD1 inhibiti…

John Monash Science School (JMSS) is Victorias first specialist science and maths school, and one of only three such specialist schools in Australia. An expression of a unique educational partnership between the Victorian Department of Education and Training (DET) and Monash University, John Monash Science School exists to advance students with an interest in pursuing endeavours within the fields of science, mathematics and associated technologies. Operating under the vision of becoming a nationally and internationally recognised centre for excellence in innovative, research-based teaching and learning, mathematics, associated technologies, resource development and pedagogy, John Monash Science School was officially opened in 2010 and has grown significantly, consistently producing outstanding graduates, and delivering high-quality, innovative and passion-driven education in science, mathematics and technologies. Increasingly, John Monash Science School is emerging as a ‘school f…

AcuraBio (formerly Luina Bio) is one of Australias most experienced biologics CDMOs, conveniently located in Brisbane, Queensland. We offer an inclusive set of services including process development and GMP manufacture of recombinant proteins, vaccines and live bio-therapeutics for human and veterinary use. We can produce material for pre-clinical studies and clinical trial GMP batches for Phase 1, 2 and 3 clinical studies. We have more than 20 years of contract manufacturing experience with a dedicated team of highly educated and trained personnel. We have worked with Australian, European, American and Asian clients supporting their development needs. We maintain a TGA/APVMA/OGTR inspected and approved facility that offers optimum flexibility to keep your development rate fast and your costs low while ensuring quality is never compromised.

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of tendon, cartilage and soft tissue injuries. Orthocells portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Companys other major product is Celgro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

HA TECH is an Australian based Biotechnology company developing & delivering effective Diagnostic, Pharmaceutical products and innovative technologies to reduce burden of disease. Our focus is on the diagnosis of serious infectious diseases: respiratory, including COVID-19, sexually transmitted infection (STI) and mosquito-borne diseases that affect hundreds of millions of people worldwide and are among the most urgent global health challenges. The Company has a diagnostic manufacturing facility at Castle Hill, Sydney, Australia. In the last 3 years since 2020, the company has seen rapid growth, with more than 30 diagnostic products in the pipeline and being commercialized. The company exported Australian made TGA approved products to over 25 countries since its inception. With the ability to produce 10 million antigen tests and 40 million RT-PCR tests per month, HA Tech holds the largest diagnostic manufacturing capacity in Australia. HA Tech exported millions of COVID-19 test ki…

Since being founded more than 70 years ago, we have become Australias most trusted intellectual property firm with offices across the country and a well-established presence in New Zealand and South-East Asia. Today, we combine world-leading expertise across biotechnology, chemistry, computer and electrical sciences, engineering and medical devices with integrity and a determination to help clients achieve their goals. We work with a broad range of clients – from Australian start-ups to global corporations; well known in the Australian market for our work with the Commonwealth Scientific and Industrial Research Organisation and a range of research institutes, universities and innovation hubs that support emerging businesses. Our mission is to inspire our attorneys and staff to best serve our clients as they navigate what can be the complex world of IP. Our unique approach has seen us win nine Australian Client Choice Awards six years running. Most recently, we were awarded ‘Best S…

Medlab Clinical Ltd is an Australian, publicly listed biotechnology company (ASX:MDC) developing therapeutics using its proprietary, next-generation delivery platform, NanoCelle®. With NanoCelle® the company has launched and is investigating a broad range of prescription and non-prescription solutions for unmet patient needs across a variety of therapeutic areas including pain management, mental health, gut health, diabetes, and allergies. We fabricate remarkable pharmaceuticals that triumph against current market competition. Through our talented managerial and scientific teams, we furnish our brand warrant - to provide practitioners with innovative, evidence based products they can confidently prescribe. At Medlab Clinical Ltd, we believe that all of our employees have the fundamentals to be phenomenal. Where innovative thinking thrives and people are valued. We believe that assessing our business´s performance is an important step to ensure a reputation as marketplace leaders. …

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVELs research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair and acute or life threatening conditions. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVELs lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 and the US Food and Drug Administration in 2019 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information …